Grace Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRCE research report →
About the company
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
- CEO
- Prashant Kohli
- IPO
- 2012
- Employees
- 4
- HQ
- Princeton, NJ, US
Price Chart
- Market Cap
- $38.57M
- P/E
- -3.73
- P/S
- 0.00
- P/B
- 0.61
- EV/EBITDA
- -1.66
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -14.15%
- ROIC
- -16.94%
- Revenue
- $0 · 0.00%
- Net Income
- $-7,793,000 · 42.81%
- EPS
- $-0.47 · 58.41%
- Op Income
- $-11,077,000
- FCF YoY
- 40.49%
- 52W High
- $5.18
- 52W Low
- $1.79
- 50D MA
- $2.34
- 200D MA
- $3.26
- Beta
- 0.37
- Avg Volume
- 706.28K
Get TickerSpark's AI analysis on GRCE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 8, 26 | Kavuru Vimal | other | 10,000 |
| Jan 8, 26 | Kottayil George | other | 10,000 |
| Jan 8, 26 | NEUGEBOREN EDWARD | other | 10,000 |
| Jan 8, 26 | DAVIS A BRIAN | other | 10,000 |
| May 9, 25 | Kottayil George | other | 10,000 |
| May 9, 25 | NEUGEBOREN EDWARD | other | 10,000 |
| May 9, 25 | DAVIS A BRIAN | other | 10,000 |
| May 9, 25 | Kavuru Vimal | other | 10,000 |
| Apr 14, 25 | Kumar Amresh | other | 30,000 |
| Apr 14, 25 | Macdonald R. Loch | other | 40,000 |
Our GRCE coverage
Recent articles, reports, and earnings notes.
No research on GRCE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRCE report →Similar companies
Peers in the same neighborhood.